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INTRODUCTION 
 Reduced bone mineral density is a universal problem of modern society; 
it may not be the commonest of all diseases, but it is sufficiently common to be 
important. Osteopenia and osteoporosis are the two different grades of the 
condition with the density being much more reduced in osteoporosis which is a 
systemic skeletal disease characterized by low bone mass and micro 
architectural increase in bone fragility that renders bone more susceptible to 
fracture. 
 Osteoporosis is now considered as a major health care problem in India 
with an estimated 50% of healthy women and 30% of men over 50 years 
having low bone mass. It is preventable and treatable, but there are no warning 
signs until fracture occurs. It is a silent risk factor for fracture just as 
hypertension is for `stroke'. 
 Hyperprolactinemia is found to be commonly associated with reduced 
bone mineral density. The osteoporotic effect of excessive prolactin are said to 
be due to hypoestrogenism, calcium mobilization from bone and direct effect of 
prolactin on bone. 
 By the year 2050, osteoporosis is likely to be a major demographic 
factor due to changes in the life style and the increase in the survival rate of the 
elderly. The incidence of fracture of the hip is likely to rise across the world to 
6.26 millions and 71% of these fractures are likely to occur in the developing 
world. Therefore the determination of bone mass has to be done constantly. At 
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present bone mass determination is done only with the help of DEXA Scan. 
(Dual Energy X-ray  Absorptiometry). 
 A developing nation like India cannot afford to diagnose fracture risk in 
the general population with the help of DEXA scan due to the high cost. 
Therefore a test which will be less expensive and reliable should be opted for in 
our country. 
 As hyperprolactinemia has been found to be associated with 
osteoporosis, determination of serum prolactin can be an useful assessment in 
the determination of reduced bone mineral density. Hence the interest 
developed to determine this hormone in the elderly who are `high risk' 
individuals prone to develop osteopenia and osteoporosis and the ensuring 
complication `fracture'. 
 The present study is to find out the association of hyperprolactinemia 
with reduced bone mineral density and plan preventive and treatment protocols 
to reduce the burden of osteoporosis on society. 
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REVIEW OF LITERATURE 
 Bone is a dense, semi-rigid, porous, calcified connective tissue forming 
the major portion of the skeleton of most vertebrates1. 
The main functions of bone are 
 1. Mechanical, for locomotion 
 2. Protective, for organs 
3. Metabolic, as a reserve for minerals especially calcium and 
phosphate2. 
 4. Blood cell formation 
 Bone is composed primarily of an extracellular mineralized matrix with 
a smaller cellular fraction. Of the total number of 206 bones in adult hood, 60 - 
70% dry weight of bone is made up of inorganic salt, 30 - 40% dry weight of 
bone is made up of organic substance and 10 - 20% of living bone is made up 
of water3,18,19. The organic matrix is primarily type I collagen with lesser 
amount of non  collagenous proteins. The composition of bone is given in 
Table 1.  
The three major components of bone are osteogenic cells, organic 
matrix, and minerals. The osteogenic cells include osteoblasts, osteocyts and 
osteoclasts, while the matrix consists predominantly of collagen and 
proteoglycans and constitutes approximately one third of the bone mass. The 
mineral that makes up approximately two thirds of bone is composed of 
calcium phosphate crystals deposited as hydroxy apatite [Ca10 (Po4)6 (OH)2]2. 
The other minerals include sodium, magnesium, carbonate, fluoride, Zinc etc. 
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Approximately 99% of the body's calcium is contained in bone. 
Hydroxyapatite confers on bone the strength and resilience required by its 
physiologic roles32. Bone contains 85% of phosphates, 55% of magnesium, 
50% of sodium and 30% of Zinc along with other trace elements and 20% of 
water. The concentration of calcium, phosphate and magnesium in plasma are 
dependent on the net effect of bone mineral deposition and resorption, 
intestinal absorption and renal excretion. Parathyroid hormone (PTH) and 
Calcitriol are the principle factors regulating these processes2. 
 Structurally two different types of bone matrix are observed. Hard 
compact cortical bone, found largely in the shafts of long bones that surround 
the marrow cavities. It is 80 to 90% mineralized by volume and constitutes 
80% of the skeleton. It's function is primarily mechanical and protective. 
Spongy, cancellous or trabecular bone comprises of a network of fine, 
interlacing partitions. The trabeculae, enclosing cavities contain either 
hematopoietic or fatty marrow. It is found in vertebrae, flat bones and in ends 
of the long bones trabecular bone constitutes the remaining 20% of the 
skeleton. Trabecular bone, which is 15% to 25% mineralized, is more 
metabolically active. 
 The organic matter of bone in mainly protein which are enumerated in 
Table-2. Among the non collagenous protein chondroitin sulfate,  
proteoglycans III and bone sialoprotein are bone specific. 
The major cell types involved in bone resorption and deposition are 
osteoclasts and osteoblasts. The former are associated with resorption and the 
latter with deposition of bone. Osteocytes are descended from osteoblasts4. 
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Osteoblasts 
 Osteoblasts are mononucleated cells derived from pluripotent 
mesenchymal precursors10,11. They synthesize most of the proteins found in 
bone as well as various growth factors and cytokins. They are responsible for 
the deposition of new bone matrix (Osteoid) and its subsequent mineralization. 
Osteoblasts control mineralization by regulating the passage of calcium and 
phosphate ions across their surface membrane. They contain alkaline 
phosphatase, which is used to generate phosphate ions from organic 
phosphates1. 
Osteoclasts12-17 
 Osteoclasts are found in sites in which bone is being remodelled. They 
are large multinucleated cells derived from pluripotent hematopoietic stem 
cells, typically found on or near bone surfaces within concavities. Acid 
phosphatase and collagenase are produced by them. They play a key role in 
bone resorption. Minerals are first removed followed by removal of organic 
matrix. The degradation products of the matrix enter the cytoplasm of the 
osteocyte through a process of endocytosis and are then transported across the 
cell and extruded into the extra cellular space. 
Osteocytes 
 Approximately 10% of the osteoblasts become enclosed in developing 
matrix and are called osteocytes. The large surface area provided by the 
osteocytes is responsible for the regulatory mechanism for the exchange of 
mineral ions between the extra cellular fluid and bone. 
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 Bone is a dynamic structure that undergoes continuing cycles of 
remodelling, consisting of resorption followed by deposition of new bone 
tissue. The bone turnover rate is approximately 10% - 30% per year5. 
PATHOPHYSIOLOGY OF OSTEOPOROSIS 
BONE REMODELLING6 
 
 Bone remodelling is a highly integrated process of resorption and 
successive formation of bone tissue that results in maintenance of skeletal mass 
with renewal of the mineralised matrix. This is accomplished by focal cell 
mediated degradation and regeneration of bone tissue with out compromising 
the overall architecture of the anatomy of bones. In normal remodelling the 
amount of bone resorbed and laid down is neutral or in positive balance7. 
 First precursor cells differentiate into osteoclasts, which erode a  cavity 
on the bone surface. The osteoclasts then disappear and there is a quiescent 
interval during which the irregular cavity is smoothened off and lined by a 
layer of cement like substances, which is of similar composition to bone but is 
mineral rich and collagen poor. A set of osteoblasts is next recruited which 
refill the excavated cavity with new bone. 
 Alterations in the dynamics of different parts of the remodelling 
processes account for the wide variety of age related changes, which occur in 
skeleton. The remodelling cycle is divided into four discrete phases and is 
illustrated in Fig. 1. 
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 Quiescence 
 Activation 
 Resorption 
 Reversal and formation 
 
Quiescence 
 During the quiescent phase, the bone surface is covered by a layer of 
thin flattened living cells, which arise by terminal transformation of 
osteoblasts. These cells retain their hormonal receptors, but have lost the ability 
to synthesize collagen. Between the living cells and the bone is a thin layer of 
unmineralized connective tissue, which closely resembles osteoid. 
Activation 
 This is the conversion of a small area of bone surface from quiescence to 
bone resorbing activity. 
 The precise mechanism by which activation occurs is still unclear. 
However it is thought that the living cells of a quiescent area are stimulated to 
digest the unmineralised connective tissue overlying the bone. They then 
retract to expose the mineralized bone surface, which is chemotactic for 
osteoclast precursor cells, which undergo fusion into osteoclasts when they 
reach the surface of the bone. 
Resorption 
 Once assembled on the mineralised bone, the osteoclasts begin to resorb 
it. The process is by expelling protons across the ruffled border into the 
resorption area by a proton - trans locating ATP ase. This lowers the local pH 
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to 4.0 or less, which increases the solubility of hydroxyapatite and allows 
demineralization to occur. Lysosomal acid proteases are released that digest the 
now accessible matrix proteins4. Resorption is illustrated in Fig.2. This leads to 
a lacuna in trabecular bone or a cutting cone in cortical bone. When the cavity 
has reached a depth of between 50µm and 100µm local resorption ceases. 
Reversal 
 This is the period between completion of resorption and the state of 
formation at a particular location. During this period mononuclear cells and a 
thin layer of mineral rich cement substance is deposited which smooths the 
osteoclastic resorption surface. 
 The osteoblast precursors are also assembled prior to bone formation. 
The mechanism of coupling bone formation to resorption is unclear, however 
the phase of bone formation is an inevitable consequence of the preceding bone 
resorption. 
Formation 
 Bone formation occurs in two stages. Soon after the cement substance 
has been deposited the newly formed osteoblasts begin to deposit a layer of 
unmineralised bone matrix. After deposition, the collagen fibrils making up the 
matrix aggregate and cross - link before they become mineralised. The new 
matrix begins to mineralise after approximately one week. 
Regulation of Bone Metabolism 
 Many factors are involved in the regulation of bone metabolism which 
are enumerated in Table - 3. 
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Two products of osteoblasts namely receptor activator of nuclear factor 
(RANK) and osteoprotegerin (OPG) have been identified that appear to be the 
final common pathway in coordinating osteoblasts and osteoclast activity3. 
RANK - κB ligand binds to a receptor on osteoclast progenitor cells and 
increase osteoclast differentiation and activity. OPG serves as a decoy receptor 
for RANK ligand. When OPG binds to RANK ligand, the osteoclast 
stimulation activity is prevented. The relative ratios of these two molecules 
determine bone turnover2. Biochemical markers of bone turnover are 
ennumerated in Table-42,20-2,110,121. 
BONE MINERAL DENSITY 
 Bone Mineral Density (BMD) is the amount of mineralised bone tissue 
in a given area, usually calculated as grams per square centimeter. It is a 
measure of bone density which is the amount of bone tissue in a certain volume 
of bone and it reflects the amount of calcium in bones64.  
 Peak bone mass in males and females occur by the third decade of life 
and plateaus for about 10 yrs, during which time, turn over of bone is constant 
with bone formation equaling bone resorption. This is followed by net bone 
loss of about 0.3% to 0.5% per year27.  Decreased bone mass and increased 
fragility can occur because of 
 1. Failure to achieve optimal peak bone mass. 
 2. Bone loss caused by increased bone resorption 
3. Inadequate replacement of lost bone as a result of decreased bone 
formation23. 
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Factors which play a role in determining peak bone mass, remodelling 
and fracture risk are given in Table-5.24-26. 
Bone mass is increased by physical exercise, intake of good calcium 
during childhood and puberty and also in obesity. 
Bone mass is reduced27, by late menarche, early menopause, nulliparity 
caffeine ingestion, cigarette smoking, alcohol use, immobilisation and 
insufficient dietary intake of calcium, phosphate and Vitamin D. 
Bone mineral density is calculated from the bone mineral content and 
the area of the bone scanned and expressed in units/gm/cm2, which can be 
plotted in relation to age with respect to reference population. Bone mineral 
density decrease with age when the fracture risk rises rapidly150-154. There is a 
decrease in mineral to matrix ratio (degree of mineralization in reduced) in 
osteoporotic tissue155-162. When BMD is reduced, depending upon the degree of 
reduction it is either known as osteopenia or osteoporosis. 
Given the increasing aging of population, osteoporosis and fracture are 
expected to increase. Large bone sizes may be associated with lower risk of 
fracture28. Every standard deviation of decrease in bone mineral density 
increase fracture risk two or three folds. Beginning with menopause, women 
have increased bone loss of 3 - 5%  per year for about 5-7 years27. Over a 10 
year period 18% of 65 year old women with osteoporosis will experience a 
fracture, increasing to 33% among those with bone mineral density more than 
four standard deviations below the peak mean. The life time hip fracture risk 
for a 50 year old women is nearly 15%29. 
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 Reduction in BMD can be measured based on the following criterias30,31. 
 1. Normal range plot : Here the subjects BMD and age are plotted 
with respect to reference population 
 2. T-scores : It measures, the deviation of the subjects BMD value 
from the mean BMD for young adult population, in units of the population 
standard deviation (SD). 
    Measured BMD - Young adult BMD 
 T score =  ______________________________ 
     Young adult SD 
 
 3. Z - scores : It is the mean BMD and standard deviation for a 
healthy age matched population which is used as a reference value instead of 
the mean BMD and SD for a young normal group. 
  
    Measured BMD - Age matched mean BMD 
 Z score =  __________________________________ 
         Population  SD 
 
Categorisation32 of the normal and reduced mineral density groups are 
shown in Table - 6 and also illustrated in Fig.333. 
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OSTEOPOROSIS36,37 
 There are many definitions for osteoporosis and most of them attempt to 
describe bone mass as it relates to fracture risk. 
Definition 
 In April 1993 the Consensus Development Conference defined 
Osteoporosis as a "Systemic Skeletal disease characterized by low bone mass 
and microarchitectural deterioration of bone tissue with a consequent increase 
in bone fragility and susceptibility to fracture". The World Health Organisation 
defines Osteopenia as a bone density which is less than normal but not 2.5 SD 
below normal bone density and osteoporosis as a `bone mineral density less 
than 2.5 SD below mean peak value in young adults'. While this definition is 
less descriptive it is the one most often used by radiologists when they measure 
bone density and it gives the physician an idea of fracture risk  
Bone Remodelling and Osteoporosis36-43 
 The hall mark of osteoporosis is reduction in skeletal mass caused by an 
imbalance between bone resorption and bone formation. Loss of gonadal 
function and aging are the two most important factors that contribute to the 
development of osteoporosis. Starting around the 5th or 6th decade of life, loss is 
at the rate of 0.3 - 0.5% / yr. In women after menopause and in men after 
castration the rate of bone loss increases by 10 fold. Thus there is increased rate 
of bone resorption compared to bone formation. 
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 The bone loss that accompanies  aging is its association with a 
progressive decline in the supply of osteoblasts in proportion to the demand for 
them. While age related bone loss affects cortical bone, in postmenopausal 
women in whom there is excess osteoclast activity it is the trabecular bone that 
is lost. 
Causes of Osteoporosis44,46 
 Several hypothesis regarding the pathogenesis of osteoporosis are 
available but the basic multicellular unit theory put forward by Frost et al., 
(1962 - 63) has been gaining wide acceptance. As per their hypothesis 
osteoporosis can be due to any one of the following six mechanisms. 
1. Resorption and formation remain constant (but unequal with 
aging). 
2. Resorption increases but formation remains constant. 
3. Resorption remains constant but formation decreases. 
4. Resorption and formation both decrease but do so unequally. 
5. Resorption and formation both increase but do so unequally. 
6. Resorption increases but formation decreases.  
 
PATHOGENETIC FACTORS  
Systemic Factors 
 Two features of osteoporosis suggest a role for local factors in 
pathogenesis.  
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 1. Systemic hormones that influence the skeleton, including 
estrogen and parathyroid hormone alter the production of local factors e.g. 
cytokines, prostaglandins and growth factors. 
 Gonadal hormone deficiency is the cause for highest incidence of 
osteoporosis in post menopausal women, young women with low estrogen 
level and in hypogonadal men.47,48,97,105,107,112 Low estrogen levels are 
associated with vertebral fractures in men49. Similarly androgen deficiency may 
be important in women as well as in men50,51. Androgens are the source of 
estrogen, both in the gonads and in the periphery, and may have a direct effect 
on bone. Rarely osteoporosis can also occur in the absence of any evidence of 
gonadal hormone deficiency. Osteoporosis is associated with high levels of sex 
hormone binding globulin (SHBG)95. This association of sex hormone with 
SHBG may reflect decreased availability of sex hormones to the tissues when 
SHBG levels are high52. 
 Increase in PTH levels which increases with age, is found to accelerate 
bone loss109,118,124. The increase of the hormone is probably due to decreased 
dietary intake of and impaired intestinal absorption of calcium, often associated 
with vitamin D deficiency149. Estrogen deficiency may also play a role in the 
increase of PTH53.  
 Differential bone loss occurs in different parts of the skeleton. 
Production of IL-1, TNF - α and IL-6 may be increased in estrogen deficient 
and osteoporotic patients54-57. However, there have been negative results in 
studies of the role of cytokines in osteoporosis in humans. 
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 Calcitonin deficiency does not appear to play a role in osteoporosis58 
although pharmacologic doses of calcitonin can prevent bone loss or even 
increase bone mass in patients with high bone turn over. 
 Glucocorticoid excess can produce secondary osteoporosis but does not 
appear to play a major role in primary osteoporosis113-115. 
 Growth hormone secretion and circulating IGF-1 decreases with age and 
their levels are low in osteoporotic patients, particularly males61. Thyroid 
hormone excess has been found to exacerbate osteoporosis59,60. Risk factors for 
osteoporosis is illustrated in figure - 7 and that for osteoporotic fractures are 
enumerated in Table 7.62,77-86,119,122. 
CLASSIFICATION OF OSTEOPOROSIS44 
 On the basis of the modified classification by Nordin (1964), which 
takes account of findings by the World Health Organisation (WHO) on causes 
of osteoporosis, it is classified as  
 
 
 
 
 
 
 
OSTEOPOROSIS 
Generalised Osteoporosis Localised Osteoporosis 
Due to Immobilization 
 
Primary 
Secondary to 
diseases 
1. Post menopausal or  
   osteoclast mediated 
 
2. Senile or osteoblast  
    mediated 
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Generalised Osteoporosis 
1. Primary 
 On the basis of the pattern of bone loss and fractures, Riggs and Melton 
(1988) identified two types of osteoporosis. 
 Type 1      postmenopausal or osteoclast mediated 
 Type 2      senile or osteoblast mediated. 
 Type 1 Primary Osteoporosis is characterised by a rapid bone loss seen 
in recent postmenopausal women. The turnover of trabecular bone is 
accelerated. Therefore distal radial and vertebral fractures are common.   
Type 2 Primary osteoporosis is characterised by age related bone loss, 
calcium deficiency and or hyperparathyroidism. Fractures of the proximal 
femur, especially fracture of the neck of femur and inter trochanteric fracture 
are more common in this type of osteoporosis. Osteoporosis secondary to 
diseases are enumerated in Table -863,88-93. 
Diagnosis65,66 
 As indicated by WHO, osteoporosis can be diagnosed before fracture 
occurs by measuring bone density. The frequency of diagnosis, therefore, 
depends on the frequency, site, and timing of bone density measurements.  
The history should indicate detailed analysis of calcium intake and 
nutrition, change in height or weight, physical activity and life style, smoking 
history, mensural and reproductive history, personal or family history of 
fragility fracture, or other metabolic or endocrine disorders that may affect the 
skeleton. 
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1. Physical examination : should include careful height 
measurement, assessment of the spine, evaluation for thyroid and adrenal 
disease. 
2. Radiographic examination : Plain radiographs are not sensitive 
enough to diagnose osteoporosis until total bone density has reduced by 50% 
but bone densitometry is useful. Single and dual photon densitometry has been 
used. They are less accurate analysis and radiation exposure is more than x-ray 
absorptiometry. 
3. Assessment of BMD : The technique used to assess  BMD are : 
 1. Conventional skeletal radiography 
 2. Radiographic photodensitometry 
 3. Radiogrammetry 
 4. Single energy absorptiometry 
 5. Dual energy x-ray absorptiometry 
 6. Quantitative computed tomography 
 7. Photon scattering methods 
 8. Neutron activation analysis 
 9. Ultrasound evaluation of bone 
 
Most widely used techniques of assessing BMD are dual - energy x-ray 
absorptiometry - DEXA and quantiative computerised tomography - QCT. 
Dexa is more precise and the diagnostic measure of choice. The measuring 
device by Dexa has already been ennumerated. 
 
18
4. Ultrasound Evaluation of Bone44 
Several methods have been developed that variously examine the 
velocity attenuation or reflection of ultrasound in bone. 
Ultrasound attenuation 
A short burst of ultrasound is passed through the heel (os calsis), the 
frequency varying from 200 to 1000 KHz. The amplitude spectrum is 
compared with that from water alone to give a plot of attenuation in the os 
calcis against frequency, and the slope of the linear portion of this graph is 
taken to characterise the bone. 
Attenuation is related both to the amount of bone in the path of the 
ultrasound and to the trabecular structure. The technique discriminates patients 
with or without osteoporosis as well as measurements of BMD. 
This is advantagenous when compared to QCT and DEXA examinations 
which require more space and investment. 
The calcaneum has many advantages for the assessment of osteoporosis. 
First of all it is very easy to access. It is a weight bearing bone like the neck of 
the femur and the vertebral bodies. It is approximately 90% trabecular bone. 
The posterior half of the bone has parallel surfaces on the medial and lateral 
aspects and hence the passage of ultrasound waves is most unhindered and best 
suitable for BMD measurements as illustrated in Figure 3(a).  
 Additional   biochemical   markers   in   the   blood   are   given  in 
Table -9.34,35,45,95. 
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Management of Osteoporosis is given in Table 1067. 
Recommendation for Prevention71,123 
 The National Osteoporosis Foundation has made the following 
recommendations to physicians. 
 1. Counsel all women on the risk factors for osteoporosis 
2. Perform an evaluation for osteoporosis on all postmenopausal 
women who present with fracture, using BMD 
3. Recommend BMD testing to all women younger than 65 years 
who have one or more risk factors for osteoporosis in addition to 
menopause. 
4. Recommend BMD testing to all women 65 years and older 
regardless of additional risk factors. 
5. Advice all patients to obtain an adequate dietary intake of 
calcium (atleast 1200 mg/day) 
6. Recommend regular weight bearing exercise and muscle - 
strengthening exercise to reduce the risk of fall and fracture. 
7. Advice patients to avoid smoking and reduce alcohol intake. 
8. Consider all postmenopausal women who present with vertebral 
or hip fracture to be candidates for osteoporosis treatment. 
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9. Indicate therapy to reduce fracture risk in women with T score 
below 2 in the absence of risk factors and in women with Tscore 
below 1.5 if other risk factors are present. 
10. Pharmacological options for osteoporosis prevention and 
treatment are : 
  Hormone replacement therapy 
  Alendronate 
  Raloxifenes 
  Calcitonin  
GOALS FOR THERAPY67 
1. Prevention of fracture 
2. Optimization of skeletal development and maximization of peak 
bone mass at skeletal maturity. 
3. Prevention of age related and secondary causes of bone loss. 
4. Preservation of the structural integrity of the skeleton 
5. Improvement in the quality of life 
6. Decrease in morbidity and mortality 
Osteoporosis therapy can reduce the risk of fracture by as much as 
50%108. 
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HYPERPROLACTINEMIA AND IT'S ASSOCIATION WITH 
BONE MINERAL DENSITY 
In the last 20 years several biochemical works on bone mineral density 
have suggested that hyperprolactinemia has been associated with reduced bone 
mineral density72-75,97-102,111,116,117. 
The osteoporotic effect of excessive prolactin may be due to 
hypoestrogenism, calcium mobilization from the bone, prolactin receptors in 
the bone and prolactin dependent increase in parathyroid hormone related 
peptide level76. 
The anterior pituitary hormones are classified into 3 categories. 
1. The Growth hormone, prolactin, chorionic somatomammotropin 
group. 
2. The glycoprotein hormone group 
3. The pro-opiomelanocortin peptide family. 
Growth hormone, prolactin and chorionic somatomammotropin are a 
family of protein hormones having considerable sequence homology4. 
Prolactin125 
Prolactin is a protein hormone of the anterior pituitary gland that was 
originally named for its ability to promote lactation in response  to the suckling 
stimulus of hungry young mammals. It appears in a multiplicity of post 
translational forms ranging from size variants to chemical modifications such 
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as phosphorylation or glycosylation. It is not only synthesized in the pituitary 
gland but also within in the central nervous system, the immune system, the 
uterus, and its associated tissues of conception and the mammary gland It's 
biological role is not only in reproduction but it also controls a variety of 
behaviors and even plays a role in homeostasis. Prolactin - releasing stimuli are 
nursing stimulus, light, audition, olfaction and stress. Dopamine of 
hypothalamic origin provides inhibitory control over the secretion of prolactin. 
Prolactin Chemistry and Molecular Biology 
Prolactin Gene 
 Based on its genetic, structural, binding and functional properties 
prolactin belongs to the prolactin / growth hormone / placental lactogen family. 
(Group I of the helix bundle protein hormone). 
 Genes encoding the 3 hormones evolved from a common ancestral gene 
by gene duplication. In the human genome, a single gene, found on 
chromosome 6 encodes prolactin. The prolactin gene is 10 Kb in size and is 
composed of 5 exons and 4 introns. The mature human prolactin is composed 
of 199 amino acids as illustrated Figure -4. 
Structure 
 The prolactin molecule is arranged in a single chain of amino acids with 
3 intramolecular disulfide bonds between 6 cysteine residues in humans. 
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Cys4 - Cys11 
Cys58 - Cys174 
Cys191 - Cys199 
Secondary and Tertiary Structure of Prolactin 
 50% of amino acid chain is arranged in α - helices while the rest of it 
forms loops. The 3 dimensional model of prolactin contains 4 long α - helices 
arranged in anti parallel fashion. This is illustrated in figure -5.  
Prolactin Variants 
 The major form of prolactin found in the pituitary gland is 23kDa. 
Variants of prolactin have been found. These are a result of alternative splicing 
of the primary transcript, proteolytic cleavage and other post translational 
modification of the amino acid chain. 
Monomeric prolactin -       Little  prolactin 23Kd 
Dimeric prolactin  -       Big Prolactin 48 to 56 Kd 
Polymeric prolactin  -       Big - Big Prolactin > 100 Kd  
The monomeric form is the most bioactive prolatin. A glycosylated form 
of prolactin has also been identified and it is less biologically active than little 
prolactin. 
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Site of synthesis and secretion of prolactin 
 The cells of the anterior pituitary gland which synthesize and secrete 
prolactin are called lactotrophs or mammotrophs. They constitute 20 - 50% of 
the anterior pituitary  cells depending on the sex and the physiological status of 
the animal. Most of the prolactin expressing cells appears to arise from growth 
hormone producing cells. Two cell forms expressing the prolactin gene are 
large polyhedral cells found through out the gland and smaller angulated or 
elongated cells clustered mainly in the lateral wing and median wedge. 
Prolactin and growth hormone can also be secreted from the intermediate cell 
population called mammosomatotrophs of the pituitary. 
 Prolactin immunoreactivity was found in telencephalon in the cerebral 
cortex, hippocampus, amygdala, septum, caudate putamen, brain stem, 
cerebellum, spinal cord and choroid plexi. Placenta, amnion, decidua, uterus, 
mammary gland, immune system, cells of thymus, spleen and peripheral 
lymphocytes contain prolactin. 
Prolactin Receptors96 
 The prolactin receptor is a single membrane - bound protein that belongs 
to class I of the cytokine receptor superfamily. The gene encoding the human 
prolactin receptor is located on chromosome 5 and contains at least 10 exons. 
The distribution of prolactin receptors are given in Table 11. 
 Activation of prolactin -  receptor is by means of  extracellular domain 
and Intracellular domain. The  intracellular domain, is the key player in the 
initiation of the signal transduction mechanism associated with the prolactin 
receptor. Although the intracellar domain of the prolactin receptor is devoid of 
any intrinsic enzymatic activity, ligand - mediated activation of prolactin 
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receptor result in tyrosine phosphorylation of cellular protein including the 
receptor itself. The membrane proximal region of the intracellular domain is  
constitutively associated with a tyrosine kinase termed Janus  kinase 2 (JAK 2). 
Phosphorylation of JAK 2 occurs  within 1 minute after prolactin binding, 
suggesting a major role for JAK 2. 
Biological Action of Prolactin 
Reproduction 
 The best known effect of prolactin is on the mammary gland. It is also 
important for the maintenance and secretary activity of the corpus luteum. It 
also affects other actions related to reproduction such as mating and maternal 
behaviours. 
Lactation 
 The effect of prolactin on the mammary gland  (mammogenesis), 
synthesis of milk (lactogenesis) and maintenance of milk secretion 
(Galactopoiesis). 
 In the process of lactogenesis, prolactin stimulates uptake of amino 
acids, synthesis of milk proteins casein and α - lactalbumin, uptake of glucose 
and synthesis of milk sugar lactose and milk fats. 
 Active lactation is due to a reduction in estrogen and progesterone and 
in prolactin levels after delivery. Suckling increases milk production after 
parturition and is essential for continued lactation. In the absence of suckling, 
prolactin concentrations which rise through out gestation return to normal by 
the 7th postpartum day. Suckling increases prolactin levels by 8.5 fold in 
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nursing mothers . Lactational amenorrhea is a form of contraception that 
depends on the frequency and duration of breast feeding. 
Homeostasis 
 Prolactin plays a role in maintaining the internal environment by 
regulating the immune system, osmotic balance and angiogenesis. 
Immune Response 
 Prolactin is a common mediator of the immunoneuroendocrine network, 
where nervous, endocrine and immune systems communicate with each other. 
Prolactin plays a role in humoral and cellular immune response. Effect of 
prolactin on lymphocytes may involve interleukin - 2. 
Osmoregulation 
 Prolactin regulates solute and water transport across cell membranes. It 
decreases the transport of sodium and increases the transport of potassium 
across mammary epithelial cells. It is responsible for fluid, sodium, chloride 
and calcium transport across intestinal epithelial membranes. Prolactin acts on 
the proximal convoluted tubules to promote sodium, potassium and water 
retention. 
Angiogenesis 
 Angiogenesis, the development of blood vessels is inhibited by 
prolactin. 
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Prolactin Secretion 
 The calculated production rate of prolactin ranges from 200 to 536 µg / 
day/ m2. Reference values are given in Table -12143. 
Factors Influencing Secretion 
Circadian Rhythm125-127 
 Prolactin is detectable  in plasma at all times during the day but is 
secreted in discrete pulses  superimposed on basal secretion and exhibits a 
diurnal rhythm with peak values in the early morning hours. There is a true 
circadian rhythm in humans because it is maintained in a constant environment 
independent of the sleep rhythm. Lowest concentration is found at mid day. 
External Stimuli128 
 The suckling stimuli is the most important physiologic regulator of 
prolactin secretion. Within 1 - 3 minutes of nipple stimulation, prolactin levels 
rise and remain elevated for 10 - 20 minutes. This reflex is distinct from the 
milk let - down, which involves oxytocin release from the neurohypophysis. 
 Stress affects prolactin secretion though the significance of it is 
uncertain. It may be related to the action of prolactin on cells of the immune 
system or some other aspects of homeostasis. 
Regulation of prolactin Secretion 
 Prolactin secretion is regulated by physiological states like mensural 
cycle, pregnancy, lactation and stimuli like light and stress. 
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Intra Pituitary Regulation 
 The secretion of  prolactin is regulated by autocrine - paracrine factors 
within  the anterior lobe. Local regulators of prolactin are given in Table - 
13129-133. 
Neural Control 
 It is well known that prolactin secretion, unlike the secretion of other 
pituitary hormones, is primarily under tonic inhibitory control by the 
hypothalamus. Dopamine is the principle, physiological prolactin inhibiting 
factor134 (PIF) released from the hypothalamus. Dopamine inhibits prolactin 
secretion from lactotrophs both in vivo and vitro135. Secretary bursts of 
prolactin are caused by the acute withdrawal of dopamine inhibition or 
stimulation by prolactin releasing factors or combination of both events. 
Neuro Endocrine Regulation125,134,136 
 Secretion of prolactin, like that of other anterior pituitary hormones, is 
regulated by hormonal feed back and neural influences from the hypothalamus 
as illustrated in figure 6 and Table - 14. In the elderly it is found that there is a 
rise in serum prolactin levels at the rate of 5.3% per year due to  the loss of 
hypothalamic pituitary regulatory function due to aging. 
Feed Back Control137 
 Feed back is exerted by prolactin itself at the level of the hypothalamus. 
Negative feed back control of prolactin secretion is mediated by a unique short 
loop mechanism within the hypothalamus. This is by increasing the 
concentration of tyrosine hydroxylase activity in the neurons that produce 
dopamine. Short feed back-loop inhibition of Gonadotropin releasing hormone 
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secretion by prolactin has been suggested as the reason  for the inhibition of 
gonadotropin secretion that occurs in women who are nursing and in patients 
with prolactin secreting adenomas of the pituitary gland2. 
Prolactin Clearance 
 138Prolactin clearance rate ranges from 40 - 71 ml/min/m2 prolactin is 
cleared rapidly with  a half-life of 26 to 47 minutes. Prolactin secretion is 
episodic in 4 to 14 secretary pulses during the day each lasting 67 to 76 
minutes over 24 hrs139-141. Prolactin reaches its highest level during sleep and 
lowest is at mid noon142. 
Prolactin stimulation 
 Other than the local regulators given in Table 13 for prolactin secretion 
there are other stimulators and inhibitors, which are given in Table 15. 
HYPERPROLACTINEMIA 
 In the absence of a prolactinoma, hyperprolactinemia may be caused by 
other pituitary or sellar tumours that inhibit dopamine because of pressure on 
the pituitary stalk or interruption of the vascular connection between the 
pituitary and hypothalamus. 
Idiopathic hyperprolactinemia144,145 
 An elevated circulating prolactin level in patients in whom no cause is 
identified is considered  idiopathic and they are resistant to dopamine. 
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Macroprolactinemia146 
 Large circulating prolactin molecule with markedly reduced bioactivity. 
Clinical Significance147 
 Hyperprolactinemia is the most common hypothalamic pituitary disorder 
encountered in clinical endocrinology. The signs and symptoms of 
hyperprolactinemia are given in Table -16. 
The etiology of  hyperprolactinemia is given in Table -17. 
Mechanism of reproductive dysfunction due to hyperprolactinemia106 
 Inhibition of pulsatile Gonadotrophin Releasing Hormone (GnRH) 
secretion, interference with gonadotropin action in ovary, interference with 
estrogen positive feed back, inhibition of Follicle Stimulating Hormone (FSH) 
directed ovarian aromatase, inhibiton of progesterone synthesis by granulosa 
cells, and inhibition of 5 - a reductase enzyme in men thereby reducing 
conversion of testosterone to dihydro testosterone. 
 Hypogonadism is a well established cause for secondary osteoporosis. 
Hypogonadism results in premature ovarian failure or acquired GnRH 
deficiency and results in reduction in bone density with preferential trabecular 
bone lose. Clinically it leads to amenorrhoea and a state of functional 
menopause. 
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Association of hyperprolactinemia with reduced bone mineral density148 
 The precise means by which estrogen deficiency causes increase bone 
turnover is not known, possible mechanism includes a direct effect on 
osteoblasts via estrogen receptors. Trabecular bone is found to be more affected 
than cortical bone. There is a 15-30% reduction in trabecular bone density and 
17% reduction in cortical bone density. Estrogen reduces calcium and 
phosphorus excretion. Estrogen deficiency accelerates, the bone turnover. 
Deficiency during puberty can impair the attainment of normal peak bone 
density there by making women vulnerable to skeletal fracture. 
 Androgens play an important role in the maintenance of normal bone 
mass in women. It's effect is similar to that of estrogen, its deficiency slower in 
producing calcium loss. Cortical  osteopenia was significantly related to the 
duration of hyperprolactinemia but not to the absolute level of prolactin or 
androgen. 
 Patients of both sexes with hyperprolactinemia have reduced bone 
density and treatment not only stops bone loss but also reverses it. 
Hypogonadism should be treated not only to restore fertility but also to prevent 
osteoporosis107,117 
 Bone mineral density was studied in hyperprolactinemic women and 
compared with normal subjects. The mean bone mineral density in gm/cm2 in 
hyperprolactinemic women was 9% less than is normal subjects. Negative 
correlation was found between bone mineral density and the duration of 
hyperprolactinemia. The analysis of bone metabolic parameters, bone turnover, 
bone formation and bone absorption showed an increase in hyperprolactinemic 
states. 
 
32
AIM OF THE STUDY 
  On having reviewed about reduced bone mineral density especially 
osteoporosis and its association with hyperprolactinemia, the work on  
prolactin in reduced bone mineral density has been taken up with the view of 
establishing the following . 
 1. Reference range for serum prolactin for the study. 
2. To analyse the level of serum prolactin and other biochemical 
parameters namely s.calcium, s.phosphorus, s.alkaline 
phosphatase, in subjects with reduced Bone Mineral Density i.e. 
osteopenic subjects and osteoporotic subjects and to assess 
whether their level differed from their reference range 
statistically. 
3. To correlate the level of  serum prolactin with s.calcium, 
s.phosphorus, s.alkaline phosphatase, and Bone Mineral Density. 
4. To determine whether it is possible to established a cut off level 
for serum prolactin to differentiate subjects of reduced bone 
mineral density from normal subjects. 
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MATERIALS AND METHODS 
 A total of 124 subjects who attended an `Osteoporosis Camp', for the 
purpose of screening for osteoporosis, were included in the present cross 
sectional study of hyperprolactinemia and its association with reduced BMD. 
 The subjects were grouped as follows : 
Group I : 1. Apparently normal elderly men 
   2. Apparently normal elderly women 
Group II : 1. Elderly men with osteopenia 
   2. Elderly women with osteopenia 
Group III : 1. Elderly men with osteoporosis 
   2. Elderly women with osteoporosis 
 BMD was estimated using ultrasound of the os calcis and depending on 
the speed of sound the subjects were diagnosed as having either osteopenia or 
osteoporosis. Bone densitometry reports provide a T Score - the number of 
standard deviations above or below the mean bone mineral density matched to 
young controls. 
Normal       : A value for BMD ± 1 SD of the young adult reference 
mean 
Osteopenia   : A value for BMD > 1SD & -2.5 SD lower than the young 
adult mean 
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Osteoporosis : A value for BMD > 2.5 SD lower than the young adult 
mean 
Severe Osteoporosis : A value for BMD > 2.5 SD lower than the young adult 
mean in the presence of one or more fragility fractures 
 The following inclusion and exclusion criteria were applied while 
selecting the subjects. 
Inclusion Criteria 
1. Apparently healthy elderly subjects 
2. Both male and female subjects 
3. Subjects between 55 - 80 years of age 
 
Exclusion Criteria 
 
1. Diabetes Mellitus 
2. Chronic Renal failure 
3. Acute and chronic liver disease 
4. Alcoholism 
5. Drugs - anticonvulsants 
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SPECIMEN COLLECTION AND STORAGE 
 After obtaining informed oral consent of the subjects five ml of 
peripheral venous blood samples was collected from each of the 124 subjects 
under strict aseptic precaution into clean dry test tubes with out adding any 
anticoagulant and the samples were allowed to stand for half an hour. The 
serum was separated by centrifugation at 2500 rpm for 10 min. Samples were 
labeled and allotted identification number. 1 ml of the serum from each sample 
was transferred with the help of a micro pipette into clean dry tubes and 
preserved at - 20°C for analysis at a later date. Samples were analyzed in two 
batches within 30 days of collection. Serum prolactin levels were estimated in 
two batches by ELISA. The remaining specimens were analyzed for s.calcium 
and s.phosphorus and s.alkaline phosphatase.  
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ESTIMATION OF SERUM PROLACTIN 
 Serum prolactin was estimated by ELISA method using pathozyme 
prolactin of OD 427 of Omega Diagnostics. 
This test has been calibrated against in house standards and against the 
World Health Organisation 1st International Reference Preparation (WHO 1st 
1RP 75 / 504). 
PRINCIPLE OF THE TEST 
 Pathozyme prolactin assay is a solid phase sandwich enzyme immuno 
assay in which specific anti prolactin antibodies coated on to micro filtration 
wells form an antigen antibody complex with prolactin present in the specimen. 
On addition of the conjugate ie monoclonal anti prolactin labelled Horse radish 
peroxidase enzyme, the prolactin is sand witched between the solid phase anti 
prolactin antibodies and antiprolactin labeled enzyme conjugate forming a 
Antibody - Antigen - Antibody complex. After incubation and washing off of 
the unbound antibody the substrate (Tetra Methyl Benzidine) is added and 
incubated. After stopping the reaction by the addition of stop solution (1ml 
HCl) the colour developed is measured colorimetrically at the wavelength of 
450 nm. The concentration of prolactin in the sample is directly proportional to 
the colour intensity of the test sample. 
MICROTITRE PLATE 
 Breakable wells coated with specific antibodies contained in a resealable 
foil bag with a desiccant. 
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REAGENTS AND CONSUMABLES 
Calibrators Concentration Contents Quantity 
A 0 ηg/ml Reference standard Human serum 
free of prolactin lyophilised 
1 ml 
B 5 ηg/ml Reference standard prolactin 
diluted in human serum 
lyophilised 
1 ml 
C 15 ηg/ml Reference standard prolactin 
diluted in human serum 
lyophilised 
1 ml 
D 50 ηg/ml Reference standard prolactin 
diluted in human serum 
lyophilised 
1 ml 
E 100 ηg/ml Reference standard prolactin 
diluted in human serum 
lyophilised 
1 ml 
F 200 ηg/ml Reference standard prolactin 
diluted in human serum 
lyophilised 
1 ml 
  
 
  
Conjugate  Anti-prolactin HRP conjugate 
Anti-prolactin conjugated to HRP 
Ready to use Pink 
11 ml 
Substrate - 
TMB 
 Substrate solution 3, 3', 5, 5' tetra 
methyl benzidine in a citrate 
buffer ready to use colourless 
11 ml 
Stop 
solution 
 Hcl 1 ml stop solution : 
hydrochloric acid (diluted in 
purified water) Ready to use 
colourless 
11 ml 
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REAGENT PREPARATION 
 All reagents were brought to room temperature (20°C to 25°C) and 
mixed gently prior to use with out inducing foaming. 
 1 ml of distilled water is added to each standard vial in order to 
reconstitute the lyophilised standards. Allow to stand for at least 20 minutes 
and mix gently store at - 20°C when not in use. Rehydrated standards can be 
stored for 30 days at 2°C to 8°C. For long term storage aliquot and freeze at - 
20°C. Freeze thaw only once. Thawed standards must be mixed prior to testing. 
ASSAY PROCEDURE 
1. Bring all the kit components and the samples to room temperature (20°C 
to 25°C) prior to the start of the assay. 
2. One set of multi level calibrator / standards should be run with each 
batch of sample. Secure the desired number of coated wells in the 
holder. Record the position of the standard and the test serum on the 
EIA Data Recording sheet provided.  
3. Unused strips should be resealed in the foil bag containing the desiccant, 
using the resealing zip - lock before being replaced at 2°C to 8°C. 
4. Dispense 50 µl of standards and test serum into the assigned wells. 
5. Dispense 100 µl of Anti - prolactin conjugate into each well. 
6. Mix for 10 seconds. It is very important to mix completely. 
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7. Incubate the plate for 45 minutes at room temperature (20°C to 25°C). 
8. At the end of incubation period, discard the contents of the wells by 
flicking  plate contents into a Biohazard container. Then strike the wells 
sharply against absorbent paper. Ensure adequate disinfectant is 
contained in the biohazard container. 
9. Hand washing. Fill the wells with a minimum of 300 µl of distilled 
water per well. Flick plate contents into a Biohazard container. Then 
strike the wells sharply against absorbent paper. Wash the empty wells 5 
times. 
10. Strike the wells sharply onto absorbent paper or paper towel to remove 
all residual water droplets. 
11. Machine washing ensure that 300 µl of distilled water is dispensed per 
well and that an appropriate disinfectant is added to the waste collection 
bottle. Wash the empty wells 5 times. After washing remove excess 
fluid by striking the wells sharply onto absorbent paper or paper towel to 
remove all residual water droplets.  
12. Dispense 100 µl substrate solution into each well and mix gently for 5 
seconds. 
13. Incubate in the dark for 20 minutes at room temperature (20°C to 25°C). 
14. Stop the reaction by adding 10µl stop solution to each well. 
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15. Gently mix for 30 seconds to ensure that the blue colour changes 
completely to yellow colour. 
16. Read the optical density immediately (no later than 10 minutes) using a 
microplate reader with a 450 nm filter. 
ASSAY VALIDITY 
 Assay was validated as per product  
OD of Cal. A = < 0.75 
 OD of Cal. F =  > 1.5 
CALCULATION OF RESULTS 
 Calculate the mean absorbance value (A 450) for each set of standards 
and test samples. Construct a standard curve by plotting the mean absorbance 
from each standard against its concentration in ηg/ml on graph paper, with 
absorbance values on the y-axis and concentrations on the x-axis. Use the mean 
absorbance values for each specimen to determine the corresponding 
concentration of prolactin in ηg/ml from the standard curve. 
 The graph produced by the calibrators should be Hyperbolic in shape 
with the OD 450 by the calibrators proportional to their concentration. 
REFERENCE RANGE 
 Male - 6 ηg/ml  
Female - 15 ηg/ml 
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SENSITIVITY 
 The minimum detectable concentration of human prolactin by 
pathozyme prolactin is 2 ηg/ml. Concentrations of 4000 ηg/ml have been 
observed using pathozyme prolactin with no prozone (Hook) effect. 
ESTIMATE OF SERUM ALKALINE PHOSPHATASE 
 EC 3.1.3.1, Orthophosphoric-monoester phosphohydrolase 
 Kit used - Erba kit 
METHOD 
  Methodology Adaptation by Wilkinson et al., of the Bersey., 
Lowry et al.,  
Principle  
P-Nitrophenyl phosphate +H20    ALP         Nitrophenol + phosphate 
              Mg2+ 
 
 The rate of formation of phosphate by the action of alkaline phosphatase 
on 4 - nitrophenol at 37°C can then be measured at 405 nm. 
ASSAY PARAMETERS 
Mode Kinetic 
Wavelength  (nm) 405 
Sample Volume (µl) 10 / 20 
Reagent Volume  (µl) 500 / 1000 
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Lag time (Sec) 60 
Kinetic interval (Sec) 60 
No. of Readings 3 
Kinetic Factor 2713 
Reaction Temperature °C 37 
Reaction Direction  Increasing 
Linearity Low (IU/L) 0 
Linearity High (IU/L) 1000 
Absorbance Limit (max) 0.800 
Units IU / L 
 
Procedure 
Pipette Volume 
Working Reagent 1000 µl 
Sample 20 µl 
 
 Mix and read absorbance at 30, 60, 90, 120 seconds at 405 nm. 
CALCULATION 
 Activity of  alkaline phosphatase at 37°C IU/L =∆ A/min. x Factor 
(2713) 
REFERENCE RANGE 
 15 - 112 1U/L 37°C 
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ESTIMATION OF SERUM CALCIUM 
 Kit used - Erba kit 
METHOD 
 Arsenazo III method. 
Principle 
 Arsenazo III combines with calcium ions at pH 6.5 to form a coloured 
chromophore the absorbance of which is measured at 650 nm (630 - 660 nm) 
and is proportional to calcium concentration. 
Reagents : I Calcium Arsenazo Reagent 
Arsenazo III 0.20 mmol/l 
Imidozole buffer (pH 6.5 ± 0.1) 100 mmol/l 
 
Reagents : II Calcium Standard 
Calcium Salt 10 mg/dl 
 
ASSAY PARAMETERS 
Mode Kinetic 
Wavelength   (nm) 630 
Sample Volume (µl) 10 / 20 
Reagent Volume  (µl) 500 / 1000 
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Incubation Time (Mins) 1 
Incubation Temp (°C) 37 
Linearity Low (mg/dl) 0 
Linearity High (mg/dl) 16 
Concentration of Standard (mg/dl) 10 
Absorbance Limit (Max) 1.2 
Units mg/dl 
 
Procedure 
Pipette into tubes 
marked Blank Standard Sample 
Reagent 1 1000 µl 1000 µl 1000 µl 
Distilled Water 20 µl - - 
Standard - 20 µl - 
Sample - - 20 µl 
 
 Mix well read the absorbance of each tube against blank at 630 nm after 
1 minute. 
CALCULATION 
   Abs of Sample 
 Calcium = _____________  x Concentration of  
    mg/dl Abs of Standard Standard (mg/dl) 
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REFERENCE RANGE 
 8.4 - 10.49 - 11 mg/dl    
ESTIMATION OF SERUM PHOSPHORUS 
 Kit used - Erba kit 
METHOD 
 Modification by Wang et al., of Daly and  Ertingshausen's method 
PRINCIPLE 
 Inorganic phosphorus combines with ammonium molybdate in the 
presence of strong acids to form phosphomolybdate. The formation of 
phosphomolybdate is measured at 340 nm and is directly proportional to the 
concentration of inorganic phosphorus present. 
Reagent I    Phosphorus Reagent 
Ammonium molybdate 0.43mmol 
Sulphuric acid 213mmol 
Surfactant - 
 
Reagent 2   Phosphorus Standard 
Inorganic Phosphate  5 mg/dl 
(1.613 mmol/L) 
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Assay Parameters 
Mode Endpoint 
Wavelength 1 (nm) 340 
Sample Volume (µl) 10/20 
Reagent Volume (µl) 500 / 1000 
Incubation Time (Mins) 5 
Incubation Temp. (°C) 37 
Linearity Low (mg/dl) 0 
Linearity High (mg/dl) 15 
Concentration of Standard (mg/dl) 5 
Absorbance Limit (Max) 0.4 
Units mg/dl 
 
Assay Procedure 
Pipette into tubes 
marked 
Blank Standard Sample 
Reagent 1 1000µl 1000µl 1000µl 
Distilled Water 20µl - - 
Standard 2 - 20µl - 
Sample - - 20µl 
 
Mix well and incubate at 37°C for 5 minutes. Read the absorbance of 
standard and each sample at 340 nm against blank . 
CALCULATION 
 
          Absorbance of sample          Concentration of 
 Serum phosphorus =      x Standard mg/dl 
                               mg/dl      Absorbance of standard 
 
 
 
REFERENCE RANGE  
 
 
2.5 - 4.5 mg/dl 
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RESULTS 
 The biochemical parameters, namely s.alkaline phosphatase, s.calcium, 
s.phosphorus, s.prolactin levels of the 124 subjects who formed the study group 
are listed in Master Table 1 along with their respective BMD which has been 
calculated. Serial No.1 to 34 of this table gives the results in apparently normal 
subjects who form the control group. Serial No. 35 to 94 indicates the results in 
subjects of the osteopenic group and serial No.95 to 124 indicates the same in 
subjects of the osteoporotic group. The results of the subjects belonging to the 
different groups enumerated above are segregated separately in Tables II,III 
and IV respectively. The mean and standard deviation for each parameter of 
these tables are calculated and shown below in the respective Tables. 
 Bar diagrams depicting the mean values of the parameters in the 
different group of study along with their standard deviation have been shown in 
figure 8(a) to (e) . To determine whether the levels of s.prolactin or any other 
biochemical parameter of study varied between male and female controls, the 
males in this group have been segregated in Table II(a) and the mean and 
standard deviation for the parameters have been calculated and shown in the 
table. Like wise the females of the control group have been depicted in Table II 
(b). The obtained mean and standard deviation of the biochemical parameters 
in Table II (a) and II (b) have been compared with each other in Table No. V to 
arrive at the statistical significance between the levels of male and female 
controls. As statistical significance has not been obtained for any parameter in 
this table the mean levels of the parameters obtained from all the subjects of the 
control group irrespective of sex is taken as the reference range for the study. 
Hence the reference range for the parameters is obtained from Table II. 
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 The reference range so obtained is compared with the mean levels of the 
parameters obtained from the osteopenic group and osteoporotic group in Table 
No. VI and VII respectively to find out whether there is any variation in the 
level of the parameters in the pathological groups from that of the control 
group and if so whether there is any statistical significant for the difference. 
Similarly the difference in the level of the parameters between the two 
pathological groups is shown in Table VIII. 
 The statistical significance of the study parameters in the comparison 
table is obtained from the corresponding `P' value, which is arrived at using the 
students `t' test. 
 The correlation of s.prolactin with the other parameters of the study is 
shown in Table IX where the correlation has been arrived at using the Karl 
Pearson correlation coefficient. 
 The statistical evaluation of sensitivity and specificity between 
osteoporosis versus control and osteopenic group are shown in Table X to 
arrive at the appropriate cut off level. 
Scatter diagram showing s.prolactin levels and BMD in different groups 
are shown in figure 9(a) controls, 9(b) osteopenic group, 9(c) osteoporotic 
group respectively. 
 Box and whisker plot showing BMD and s.prolactin in different groups 
are shown in figure 10(a) and 10(b) respectively. 
 Correlation between s.prolactin and BMD is shown as bar diagram in 
figure 11(a) and as a line diagram in 11(b). Levels of s.prolactin in the 3 
different groups  along with the cut off point are shown in Figure 12. 
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DISCUSSION 
 Analysis of the results obtained in this study starts with scrutinizing the 
reference range obtained. The reference range of s.prolactin which is 10.08 ± 
6.82 ηg/ml though higher than 6-15 ηg/ml quoted in the kit methodology 
adopted for its determination is within the reference range of 3-23 ηg/ml given 
by W.B. Saunders Co.143 
 The reference range of serum calcium is 9.71 ± 0.731 mg/dl. This is 
within the reference range of 8.4 to 10.4 mg/dl of the Arsenazo III kit 
methodology which was used to estimate s.calcium and is well within the 
reference range of 8.6 - 10.2 mg/dl given in standard text books for s.calcium. 
 The reference range for s.phosphorus is 3.91 ± 0.459. This reference 
range is within the reference range of 2.5 - 4.5 mg/dl of the kit methodology 
adopted for its study and that of standard text books. 
 The reference range of s.alkaline phosphatase is 101.71 ± 14.69 IU/L. 
This level is within the reference range of 53-141 IU/L of s.alkaline 
phosphatase specified in standard textbooks for geriatric age group and that of 
the kit methodology where the range is 15 - 112 IU/L. 
 The reference range of - 0.2 ± 0.77 obtained for BMD is within the 
reference range of ± 1 SD of the `T' score for the young adult specified by the 
ultrasound method undertaken for its analysis. 
 Hence the mean levels of the analysed biochemical parametes namely 
10.08 ± 6.82 for s.prolactin, 9.71 ± 0.731 for s.calcium, 3.91 ± 0.459 for 
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s.phosphorus, 101.71 ± 14.69 for s. alkaline phosphatase and -0.2 ± 0.77 for 
BMD obtained from apparently normal geriatric individuals are accepted as 
valid reference range for the study. 
 Comparison of the levels of the study parameters obtained in osteopenia 
with the above reference range Table VI reveals a significant decrease of 
s.calcium, [p value: 0.03] significant increase of s.alkaline phosphatase, [ p 
value : 0.03] and a significant decrease in BMD [p value : 0.01]. 
 The significant decrease of s.calcium observed in this table can be 
explained in the following lines:- 
 It is a well-documented fact that age impairs both calcium absorption 
and renal calcium conservation143. Therefore even the control level obtained in 
the age group above 60 namely 9.71 mg/dl of s.calcium can be a value lower 
than that which would have been obtained if the age group between 30 to 60 
years had been analysed. In the osteopenic elders this impairment in calcium 
absorption and renal conservation is more predominant than in the control 
elders leading to its significant decrease. It has also been reviewed that 
lowering of s.calcium level will trigger the parathyroid to secrete more 
parathormone where by the level of calcium will be restored as the hormone 
increases calcium absorption in the intestine, increase renal calcium 
conservation and promotes bone resorption. The effect of PTH on bone to 
maintain calcium homeostasis by resorption of bone calcium leads to a 
decrease in BMD and thereby leads to osteopenia in this group. However when 
the mean level of s.calcium in osteopenia is analysed its level of 9.085 is found 
to be still within the reference range of 8.979 - 9.841 obtained for s.calcium in 
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controls and as well within the reference range in standard text books and 
methodology employed. Therefore the statistically significant decrease of 
s.calcium in osteopenia can be ignored. 
 The significant increase in SAP observed in this table is due to increase 
of osteoblastic action in bones due to the decrease in BMD. In the present study 
we find that though a significant increase of SAP is obtained in osteopenia its 
mean level of 101.71 IU/L is within the reference range of 53-141 IU/L 
obtained for SAP in the study and that of the reference range quoted in standard 
text books. Therefore the increase in this parameter can also be ignored.  
 The mean levels of -1.58 for BMD in the osteopenic group studied 
satisfies the `T' score classification by being well within -1 to -2.5 SD BMD 
that has to be obtained for osteopenia. This proves that the subjects selected in 
this group are osteopenic. The reasons for the decrease in BMD to a level lower 
than in the elderly controls has already been putfourth. 
 S.prolactin even though has marginally increased in the osteopenic 
group than that of its control level has not shown any statistical significance in 
this table. On the other hand the BMD has decreased from its reference level to 
a statistically significant degree (p -.01). In the elderly it has been reviewed that 
there is a rise in s.prolactin at the rate of 5.3% per year due to loss of 
hypothalamic pituitary regulatory function that occurs with aging. The increase 
in prolactin has been ascribed to an age-related decline in dopamine, the 
neurotransmitter responsible for inhibition of prolactin secretion 163. But in this 
osteopenic group of the study whose age group is similar to that of controls we 
find that decrease of BMD is not associated with a relevant statistical increase 
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of prolactin. When the levels in osteoporosis are compared with the reference 
range (Table VII) highly  significant increase of SAP (p value : 0.001) and 
s.prolactin (p value 0.001) are observed against a highly significant decrease in 
BMD (p value 0.001). BMD of -2.7 SD obtained in the study of osteoporotic 
group satisfies the `T' score norms because this value is > -2.5 SD of BMD 
which pertains to osteoporosis in the above scoring. This proves that the 
subjects selected for this study group are osteoporotic. 
 The highly significant increase of SAP and s.prolactin can be attributed 
to the same reasons discussed in the osteopenic group. While increase in 
osteoblastic activity is the cause for increase in SAP, decline of dopamine in 
the elders is said to be the cause for hyperprolactinemia. But as the mean level 
of SAP in osteoporosis is still within the reference range of 87.02 to 116.40 
IU/L of the study and that in standard text books and methodology adopted, 
this increase is ignored. Hyperprolactinemia in the osteoporotic group of the 
study correlates well with the finding of John Bernard who has said that the 
metabolic manifestations of hyperprolactinemia include decrease BMD99. As 
per Klibanski. A and Neer .R this association can be due to the direct action of 
prolactin on calcium mobilization through prolactin receptors which are 
independent of vitamin D and parathormone and that the hyperprolactinemic 
subjects have an increased risk of developing osteoporosis. 
 Comparison of the levels in osteopenia and osteoporosis (Table VIII) 
reveals highly significant increase of s.prolactin (p value .001) against a highly 
significant decrease (p value .001) of BMD in osteoporosis from its level in 
osteopenia which finding is similar to that obtained between osteoporosis and 
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controls. The significant decrease of BMD in osteoporosis from that in 
osteopenia is understandable as this condition is a more severe form of 
decreased BMD than osteopenia. This is also made evident by the higher `T' 
scoring of the osteoporotic group of the study than osteopenia. 
 Similarly the highly significant increase in s.prolactin levels of this 
group over that of the osteopenic group and as well over that of controls can be 
the relevant cause for the greater deterioration of BMD in osteoporosis. So it is 
presumed that greater the increase of s.prolactin level higher is the intensity of 
decrease in BMD. At this point it should be noted that there is absence of any 
significant elevation of s.prolactin in osteopenia from the reference range. 
Hence it can be said from this study that impairment of calcium homeostasis 
which is the hall mark of aging is the basic cause for decrease in BMD. 
 Further it has been stated that a net effect of the changes that occur as 
age advances increases the circulating level of PTH by 30% between 30 and 80 
years of age. Therefore in elders when s.calcium level is maintained 
predominantly by resorption of bone calcium rather than intestinal calcium 
absorption or renal calcium conservation being increased by PTH it results in 
significant decrease in BMD the grading of which are osteopenia and 
osteoporosis. In this study it is clear that in elders when there is associated 
hyperprolactinemia (osteoporotic subjects) there is more bone resorption than 
in those elders where its level is not elevated. (Osteopenic subjects). In the 
osteopenic subjects the decrease in BMD is attributed only to the action of 
PTH. Therefore it is inferred that the excess bone resorption due to 
hyperprolactinemia leads to severe decrease of BMD resulting in osteoporosis. 
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 Analysis by the Karl Pearson correlation coefficient of s.prolactin with 
the other parameters of the study revealed in Table IX shows the following :- 
1. Correlation of prolactin with calcium shows a negative fair 
correlation in control and a fair correlation in osteopenic group. 
2. Correlation of prolactin with BMD shows a negative fair 
correlation in osteopenic and osteoporotic group and a negative 
fair correlation in the overall group. 
As s.prolactin in the osteoporotic group has increased statistically above 
the reference range of the study and that in the osteopenic group, attempt is 
made to establish a cut off level between the latter groups and that of 
osteoporosis. For this line graph has been plotted with the levels of s.prolactin 
in the 124 subjects as per their grouping in Figure 12 various cut off levels 
have been selected and the sensitivity, specificity, positive predictive value and 
negative predictive value for these values have been calculated and shown in 
Table X. The most appropriate level between osteoporosis and the osteopenic 
and control group is found to be 11 ηg/ml which has a sensitivity of 86.6%, 
specificity of 52.12% positive predictive value 36.619, negative predictive 
value 92.452. The cut off level is shown in Figure 12 as intermittent lines. 
Hence s.prolactin level of 11 ηg/ml or more indicates osteoporosis. 
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CONCLUSION 
 From the discussion held so far on the results obtained from the blood 
samples of the 124 subjects analysed classified into the control, osteopenic and 
osteoporotic groups, the following inferences are made. 
* Reference range for s.prolactin is 10.08 ηg/ml for the study. 
* S.prolactin level is increased above the reference - range in 
osteopenia and osteoporosis but only in osteoporosis the 
elevation is statistically significant, the degree of elevation being 
highly significant in this condition. 
* The cut off level of s.prolactin to determine osteoporosis is 11 
ηg/ml.  
* S.prolactin's correlation with s.calcium is negative fair in the 
osteopenic group, negative poor in osteoporotic group; the over 
all correlation is negative fair. 
* S.prolactin's correlation with s.phosphorus is negative poor in 
osteopenic group, negative poor in osteoporotic group; the over 
all correlation is negative poor. 
* S.prolactin's correlation with s.alkaline phosphatase is poor in 
both osteopenic and osteoporotic group; the over all correlation is 
poor. 
* S.prolactin's correlation with BMD is negative fair in both 
osteopenic and osteoporotic group; the over all correlation is 
negative fair. 
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SCOPE FOR FURTHER STUDY 
* To determine s.prolactin level in normal adult group and compare the 
level with geriatric group. 
* To determine the parameters along with parathormone and vitamin D. 
* To determine the level of s.prolactin in relation to other physiological 
conditions. 
* To determine the level of s.prolactin and other parameters in conditions 
like chronic renal failure, polycystic ovarian disease and cirrhosis, where 
the level of s.prolactin is said to be raised. 
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ABBREVIATIONS 
 BMD   Bone mineral density 
 BMC   Bone mineral content 
 SD   Standard deviation 
 DEXA  Dual energy  x-ray absorptiometry 
 PTH   Parathyroid hormone 
 TRH   Thyrotropin - releasing hormone 
 GnRH   Gonadotropin releasing hormone 
 ACTH  Adrenocorticotropic hormone 
 ELISA  Enzyme linked immuno sorbent assay 
 SAP   Serum Alkaline phosphatase 
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TABLE  -  1 
COMPOSITION OF BONE 
 
 
 
 
 
 
 
 
 
 
 
Bone 
Cellular Components 
 
1. Osteoblasts 
2. Osteocytes 
3. Osteoclasts 
A cellular components 
Organic Matrix Inorganic Matrix 
Proteins 
Collagen Non-
Collagenous 
proteins 
Minerals 
1. Calcium 
2. Phosphate 
3. Carbonate 
4. Magnesium 
5. Sodium 
6. Potassium 
7. Fluoride 
8. Zinc 
  
 
TABLE  - 2 
THE PRINCIPLE PROTEINS FOUND IN BONES4 
 
Proteins 
Collagens Non Collagen 
1. Collagen type I 
 (Constitutes 90-95% of  
 organic materials) 
1. Mixture of various plasma  proteins 
2. Collagen type V 
 Minor component 
2. Proteoglycans 
Chondroitin sulfate proteoglycans I (biglycan) 
Chondroitin sulfate proteoglycan II (decorin) 
Chondroitin sulfate proteoglycan III (Bone 
specific) 
 3. Bone SPARC protein - Osteonectin. 
 (Secreted protein acidic and rich in  
 cysteine) not bone specific 
 4. Osteocalcin (Bone Gla protein Bone 
 Specific) 
 5. Osteopontin - not bone specific 
 6. Bone sialoprotein - Bone specific 
 7. Bone morphogenetic protein (BMPS) 
  
  
 
TABLE  - 3 
FACTORS AFFECTING OSTEOBLASTS AND OSTEOCLASTS8,9,27,87 
 
Stimulate Osteoblasts Inhibit Osteoblasts 
Parathyroid hormone 
1,25 - Dihydroxy Cholecalciferol 
Thyroid hormones 
Growth hormone, Insulin like growth 
factor- 
Prostaglandins E2 
Transforming growth factor β 
Estrogens 
Androgens 
Corticosteroids 
Stimulate Osteoclasts Inhibit Osteoclasts 
Parathyroid hormone 
1,25 - Dihydroxy Cholecalciferol 
Interleukin - 1,3, 6,11 
Tumour necrosis factor 
Transforming growth factors α 
Granulocyte macrophage colony 
stimulating factor 
Macrophage colony stimulating 
factor 
Leukemia inhibitory factor 
Stem cell factor 10,11,12,18 
Calcitonin 
Estrogens (by inhibiting IL-6 
production) 
Transforming growth factor β 
Interferon α 
Prostaglandins E2 
 
TABLE  - 4 
BIOCHEMICAL MARKERS OF BONE METABOLISM 
Markers of bone formation - serum 
 1. Carboxy - terminal propeptide of type I collagen 
 2. Amino - terminal propeptide of type I collagen 
3. Serum Alkaline phosphatase - shows increased osteoblast 
activity. 
4. Bone specific alkaline phosphatase - more accurate. 
5. Osteocalcin (bone Gla protein) marker of bone synthesis. 
Markers of bone resorption - serum 
1. C- telopeptide of collagen cross - links 
2. N - telopeptide of collagen cross - links 
3. Tartarate - resistant acid phosphatase 
4. Bone sialoprotein 
5. Hydroxy proline 
Markers of bone resorption - urine 
1. Hydroxy proline 
2. Hydroxy lysine 
3. N - telopeptide of collagen cross links. 
4. C-telopeptide of collagen cross links 
5. Total and free pyridinoline 
 6. Total and free deoxy pyridinoline 
 
  
 
 
TABLE  - 5 
FACTORS AFFECTING PEAK BONE MASS 
 
 
 
 
1. Polymorphism of genes 
 2. Vitamin D 
 3. Estrogen receptors 
 4. Collagen 
 5. Cytokines 
 6. Apolipoprotein E 
 7. Growth factors 
 
 
 
  
  
TABLE  - 6 
DIAGNOSTIC CATEGORIES OF OSTEOPOROSIS  
BASED ON MEASUREMENT 
 
Category Definition 
Normal A value for BMD or BMC + ISD of the young 
adult reference mean 
Osteopenia A value for BMD or BMC > ISD and < 2.5 SD 
lower than the young adult mean 
Osteoporosis A value for BMD or BMC > 2.5 SD lower than 
the young adult mean 
Severe Osteoporosis A value for BMD or BMC > 2.5 SD lower than 
the young adult mean in the presence of one or 
more fragility fractures 
 
 
 
  
 
FIGURE - 3 
DIAGNOSIS BASED ON BMD 
 
 
 
 
 
 
 
 
 
   
-1 
Normal 
-2.5 
Osteopenia Osteoporosis 
-1.5 -2 
  
 
TABLE -  7 
RISK FACTORS FOR OSTEOPOROTIC 
 FRACTURES 
 
Sl.No. Non Modifiable Potentially Modifiable 
 
1. 
 
Personal H/o fracture 
 
 
Current cigarette smoking 
2. H/o fracture in first degree 
relatives 
Low body weight less than 127 lbs 
3. Caucasion race Estrogen deficiency 
4. Advanced age Early menopause <45 years or 
bilateral ovariectomy 
5. Gender Prolonged premenopausal 
amenorrhea > 1 yr 
  Low calcium intake 
  Alcoholism 
  Caffeine 
  Impaired eye sight despite adequate 
correction 
  Recurrent falls 
  Inadequate physical activity 
  Poor health / frailty 
 
TABLE  - 8 
SECONDARY OSTEOPOROSIS 
 
1. Endocrine Disorders 
 Hyperparathyroidism  
 Cushings syndrome 
 Hypogonadism 
 Prolactinoma 
 Diabetes mellitus 
 Acromegaly 
 Pregnancy and lactation 
2. Hematopoietic disorders 
 Plasma cell dyscrasias; multiple myeloma and macroglobulinemia 
 Systemic mastocytosis 
 Leukemias and lymphomas 
 Sickle cell disease and thalassemia minor 
 Lipidosis; Gauchers disease 
 Myeloproliferative disorders; polycythemia 
3. Connective tissue disorders 
 Osteogenesis imperfecta 
 Ehlers - Danlos syndrome 
 Marfans syndrome 
 Homocystinuria and lysinuria 
 Menkes syndrome 
 Scurvy 
4. Drug - induced disorders 
 Glucocorticoids 
 Heparin 
 Anticonvulsants 
 Methotrexate, cyclosporin 
 Luteinising hormone - releasing hormone LHRH agonist or  
Antogenist therapy   
  Aluminium containing antacids 
 5. Immobilisation 
6. Renal Disease 
 Chronic renal failure 
 Renal tubular acidosis 
7. Nutritional and Gastrointestinal Disorders 
 Malabsorption 
 Total parental nutrition 
 Gastrectomy 
 Hepatobiliary disease 
8. Miscellaneous 
 Familial dysautonomia 
                             Reflex sympathetic dystrophy 
  
 
 
TABLE - 9   
 
ADDITIONAL BIOCHEMICAL MARKERS IN BLOOD 
 
1. Increased creatinine level Renal disease 
2. Increased hepatic transaminase 
level 
Hepatic disease 
3. Increased calcium level Primary hyper parathyroidism or 
malignancy 
4. Decreased calcium level Malabsorption  
Vitamin D deficiency 
5. Decreased phosphorus level Osteomalacia 
6. Increased alkaline phosphatase Liver disease, Pagets disease, 
Fracture 
7. Increase ESR Multiple myeloma 
8. Decreased albumin level Malnutrition 
9. Decreased TSH level Hyperthyroidism 
10. Increased testosterone level in 
men 
Hypogonadism 
 Decreased estrogen level in 
women 
 
11. Increased parathyroid hormone Hyperparathyroidism 
12. Decreased 2,5 di hydroxy 
calciferol 
Vitamin D deficiency 
13. Increased serum Iron 
Increased ferritin 
Hemochromatosis 
14. Increased serum prolactin Prolactinoma 
15. Increased serum IGF-I Acromegaly 
 
  
TABLE -  10 
MANAGEMENT 
 
 
1. Life style modifications 
  Exercise  
 Caffeine intake to be reduced 
 Smoking to be stopped 
 Alcohol to be stopped 
 Sodium intake to be reduced 
2. Prevention of fall 
3. External hip protectors 
4. Intake of Calcium and Vitamin D368 to be increased 
5. Bisphosphonate69 
6. Calcitonin70 
7. Estrogen 
8. Estrogen receptor modulators - Raloxifene, Tamoxifene 
9. Parathyroid hormone 
  
  
 
TABLE - 11 
DISTRIBUTION OF PROLACTIN RECEPTORS  
 
Central Nervous 
System 
 
Choroid plexus  
Amygdala  
Thalamus  
Hypothalamus  
Cerebral cortex 
Mid brain  
Olfactory bulb. 
 
Peripheral Organs 
 
Pituitary Gland 
Heart 
Lung 
Thymus 
Spleen 
Liver 
Pancreas 
Kidney 
Adrenal glands 
Uterus 
Skeletal muscle 
Skin 
 
 
 
 
 
 
 
 
 
TABLE - 12 
 
REPRESENTATIVE VALUES USING  
IMMUNORADIO METRIC ASSAY 
 
 
  µg/L 
Cord Blood  45 - 539 
Children Tanner Stage   
Male < 10 
1 
Female 3.6 - 12 
Male < 6.1 
2 - 3 
Female 2.6 - 18 
Male 2.8 - 11 
4 - 5 
Female 3.2 - 20 
Male 3.0 - 14.7 
Adults 
Female 3.8 - 23.0 
Pregnancy, third 
Trimester 
 95 - 473 
 
 
 
 
 
 
 
 
 
 
 
TABLE - 13 
 
LOCAL REGULATORS OF PROLACTIN SECRETION 
 
 
 Stimulators Inhibitors 
1. Galanin  
2. Vasoactive intestinal Polypeptide - 
VIP 
Prolactin 
3. Endothelin - like peptides Acetyl Choline 
4. Angio tensin II Transforming Growth Factor β 
5. Epidermal Growth Factor Calcitonin 
6. Basic Fibroblast Growth Factor  
7. Luteinising hormone - releasing 
hormone 
 
8. Cytokine - 1L-6  
 
 
 
 
 
 
 
 
TABLE  - 14 
 
REGULATORY CONTROL OF PROLACTIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothalamus 
 
Thyroid 
Releasing 
Hormone 
( +) 
Dopamine 
( - ) 
Prolactin 
Pituitary 
Lactation and pregnancy 
Ovarian and Testicular steroidogenesis 
Immune Function 
 
 
 
 
 
TABLE - 15 
 
PROLACTIN STIMULATOR AND INHIBITORS 
 
 
Prolactin Stimulators Prolactin Inhibitors 
Estrogens Dopamine 
Hypothyroidism Hypo-osmolality 
Oxytocin Endothelin - 1 
Serotonin  
Opiates  
Anti depressants  
H2 blockers - histamine  
Phenothiazines  
Neuro epileptics  
Suckling  
Stress  
Exercise  
Pregnancy  
Head Injury  
ACTH  
GHRH  
GnRH    
Plasma hyperosmolality  
 
 
 
 
 
 
 
 
TABLE - 16 
 
 
CLINICAL FEATURES OF HYPERPROLACTINEMIA 
 
 
1. Amenorrhea - 75% of women 
2. Oligomenorrhoea 
3. Primary amenorrhoea 
4. Infertility - 33% of women 
5. Decreased libido 
6. Impotence  
7. Premature ejaculation 
8. Erectile dysfunction 
9. Oligo spermia 
10. Galactorrhoea - 10% of women and 99% of men 
11. Osteoporosis 
 
TABLE  - 17 
 
ETIOLOGY OF HYPERPROLACTINEMIA147 
 
I. Physiologic : Pregnancy 
Lactation 
Stress 
Sleep 
Coitus 
Exercise 
II. Pathologic : Hypothalamic pituitary stalk damage 
Tumours 
Craniopharyngioma 
Supra sellar pituitary mass extension 
Meningioma 
Granulomas 
Irradiation 
Trauma 
Pituitary Stalk Section 
Supra Sellar Surgery 
III. Pituitary : Prolactinoma 
Acromegaly 
Macroadenoma 
Idiopathic 
Plurihormonal adenoma 
Lymphocystic hypophysitis or parasellar mass 
Macroprolactinemia 
Surgery 
Trauma 
IV. Systemic Disorders : Chronic Renal failure 
Polycystic Ovarian disease 
Cirrhosis 
Pseudo cysis 
Epileptic seizures 
Cranial radiation 
Chest-neurogenic chest wall trauma, surgery, 
herpes zoster. 
V. Pharmacologic : Neuropeptides 
Thyrotropin releasing hormones 
PRL - releasing peptide 
VI. Drug Induced 
Hyper secretion 
: Dopamine receptor blockers 
Phenothiazines, chlorpromazine, perphenazine 
Butyro phenones; haloperidols 
Thioxanthenes 
Metoclopramide 
VII. Dopamine 
Synthesis inhibitor 
 Methyl dopa 
Reserpine 
VIII. Anti Depressants  Tricylic antidepressants 
 
 
FIGURE - 1 
 
BONE REMODELLING 
 
 
 
 
 
 A diagrammatic representation of the normal remodelling 
sequence in adult bone. (After Riggs and Melton, 1988). 
 
FIGURE - 6 
 
REGULATION OF THE HYPOTHALAMIC - PITUITARY - 
PROLACTIN AXIS
COURTESY : NEUROENDOCRINOLOGY BY ROGER .D.CONE, 
MALCOLM J. LOW. 
FIGURE - 7 
RISK FACTORS FOR OSTEOPOROSIS
FIGURE - 2 
 
MAJOR CELLS PRESENT IN MEMBRANOUS BONE 
 
 
  
  
  
  
 
ROLE OF OSTEOCLAST IN BONE RESORPTION 
 
COURTESY : HARPER'S BIOCHEMISTRY, 25th EDITION 
 
 
 
 
FIGURE - 4 
 
PROLACTIN - AMINO ACID SEQUENCE AND 
SECONDARY STRUCTURE 
 
 
Domain Description  
Number of Fragments  1  
Number of Monomers  199  
Fragments  Fragment 1: On Chain A from Residue 1 to Residue 199 
Sequence and Secondary Structure    
Key: = extended strand, = turn, = disulfide bond 
= alpha helix, = 310 helix, = pi helix,  
Greyed out residues have no structural information 
 
 
 
 
 
 
 
FIGURE - 5 
 
THREE DIMENSIONAL STRUCTURE 
OF PROLACTIN
 
 
 
 
 
FIGURE - 3(a) 
 
 
BONE DENSITOMETRY  
ULTRASOUND  EVALUATION OF BONE 
 
 
 
CORRELATION BETWEEN PROLACTIN AND BMD  
IN DIFFERENT GROUPS 
 
Figure - 9 (a,b,c) 
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Figure - 10 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure - 10 (b) 
 
 
Box and Whisker Plot for BMD in different groups 
OsteoporosisOsteopeniaControl
BMD 
gm/cm2) 
3 
2 
1 
0 
-1 
-2 
-3 
-4 
Box and Whisker Plot for Serum Prolactin in different groups 
OsteoporosisOsteopeniaControl
Prolactin 
ηg/ml 
40 
30 
20 
10 
0 
